Luke Corning - Jun 15, 2023 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Role
Director
Signature
/s/ Harry J.Leonhardt, Attorney-in-Fact
Stock symbol
PSTX
Transactions as of
Jun 15, 2023
Transactions value $
$0
Form type
4
Date filed
6/16/2023, 04:07 PM
Previous filing
Jun 16, 2022
Next filing
Jun 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Award $0 +19.7K +100% $0.00 39.3K Jun 15, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PSTX Stock Option (Right to buy) Award $0 +27.4K $0.00 27.4K Jun 15, 2023 Common Stock 27.4K $2.47 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders.
F2 The Reporting Person is no longer deemed to beneficially own shares held by Pentwater Capital Management LP, Crown Managed Accounts SPC, Investment Opportunities 3 SPC, LMA SPC on behalf of MAP 98 Segregated Portfolio, PWCM Master Fund Ltd., Oceana Master Fund, Ltd., Pentwater Merger Arbitrage Master Fund, Ltd., Pentwater Metric Merger Arbitrage Fund LP, Pentwater Credit Master Fund Ltd., Pentwater Equity Opportunities Master Fund, Ltd., or Pentwater Unconstrained Master Fund Ltd.
F3 The stock option will vest and become fully exercisable on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders.